Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients

BACKGROUND: Rechallenge with EGFR inhibitors represents a promising strategy for patients with RAS wild type (WT) colorectal cancer (CRC) but definitive selection criteria are lacking. Recently, the RAS WT status on circulating tumor DNA (ct-DNA) emerged as a potential watershed for this strategy. O...

Descripción completa

Detalles Bibliográficos
Autores principales: Mariani, Stefano, Puzzoni, Marco, Giampieri, Riccardo, Ziranu, Pina, Pusceddu, Valeria, Donisi, Clelia, Persano, Mara, Pinna, Giovanna, Cimbro, Erika, Parrino, Alissa, Spanu, Dario, Pretta, Andrea, Lai, Eleonora, Liscia, Nicole, Lupi, Alessio, Giglio, Enrica, Palomba, Grazia, Casula, Milena, Pisano, Marina, Palmieri, Giuseppe, Scartozzi, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068964/
https://www.ncbi.nlm.nih.gov/pubmed/35530345
http://dx.doi.org/10.3389/fonc.2022.852583

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068964/
https://www.ncbi.nlm.nih.gov/pubmed/35530345
http://dx.doi.org/10.3389/fonc.2022.852583

Ejemplares similares